AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

Last year it was reported that AstraZeneca was considering moving the manufacturing of its Covid-19 jab overseas amid a ...

AstraZeneca and Daiichi Sankyo ’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) ...

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...

Dear reader, China’s biotechnology sector has rapidly emerged as one of the fastest-growing industries, with Chinese players ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...